NRX Pharmaceuticals Inc Dossier - Source-backed chat

NRX Pharmaceuticals Inc

NRXPNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.76

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $2.85Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $123.4M

Enterprise Value $96.7M

Shares Outstanding 39.2M diluted

Next Earnings Date12 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

NRx Pharmaceuticals is transitioning from a pre-revenue clinical-stage biopharmaceutical company to a commercial-stage entity. The investment thesis centers on the imminent commercialization of KETAFREE™ (preservative-free ketamine) in Q3 2026, which targets a $750 million annual generic market, and the upcoming NDA filing for NRX-100. The company has significantly improved its balance sheet, achieving a debt-free status and raising $22.3 million in a June 2026 public offering, which extends its operational runway. While near-term volatility remains high due to its pre-revenue nature, the regulatory momentum and strong analyst consensus support a highly asymmetric upside potential.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets4 analysts · as of 18 Aug 2026

Low · most bearish analyst$10.00

Mean target$38.25

High · most bullish analyst$49.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

Regulatory delays in the ANDA approval of KETAFREE™ or additional clinical requirements requested by the FDA for NRX-100. Continued high cash burn forces further dilutive equity offerings, depressing the share price despite long-term pipeline value.

Base CaseCentral scenario

The FDA approves the ANDA for KETAFREE™ in Q3 2026, allowing NRx to launch commercial sales and capture a modest share of the $750 million generic ketamine market. The NDA for NRX-100 is successfully submitted, and the company progresses toward its goal of breaking even by FY 2027.

Bull CaseUpside scenario

Successful FDA approval and commercial launch of KETAFREE™ and NRX-100, combined with rapid expansion of the HOPE Therapeutics clinic network, driving the company to profitability by 2027.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Imminent commercial catalyst with KETAFREE™ FDA decision expected in Q3 2026.
Strengthened financial position with debt-free status and $22.3 million raised in June 2026.
Strong regulatory designations including Fast Track for NRX-100 and Breakthrough Therapy for NRX-101.
Strategic partnership with Osmind providing real-world evidence on over 65,000 patients to support FDA filings.

Key Investment Risks

Pre-revenue status makes near-term earnings highly volatile and dependent on capital markets.
High historical stock volatility with a beta of approximately 2.14.
Risk of regulatory delays or negative determinations by the FDA.
Potential for future equity dilution if commercial revenues ramp up slower than expected.

Thesis Invalidation Triggers

FDA rejection or significant delay of the KETAFREE™ ANDA beyond 2026.
Failure to submit the NRX-100 NDA within the projected timeline.
Inability to achieve commercial traction or generate meaningful revenue by early 2027.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.